Cargando…
Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity
Binding of ligand FasL to its receptor Fas triggers apoptosis via the caspase cascade. FasL itself is homotrimeric, and a productive apoptotic signal requires that FasL be oligomerized beyond the homotrimeric state. We generated a series of FasL chimeras by fusing FasL to domains of the Leukemia Inh...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541234/ https://www.ncbi.nlm.nih.gov/pubmed/23326557 http://dx.doi.org/10.1371/journal.pone.0054000 |
_version_ | 1782255326153670656 |
---|---|
author | Daburon, Sophie Devaud, Christel Costet, Pierre Morello, Aurore Garrigue-Antar, Laure Maillasson, Mike Hargous, Nathalie Lapaillerie, Delphine Bonneu, Marc Dechanet-Merville, Julie Legembre, Patrick Capone, Myriam Moreau, Jean-François Taupin, Jean-Luc |
author_facet | Daburon, Sophie Devaud, Christel Costet, Pierre Morello, Aurore Garrigue-Antar, Laure Maillasson, Mike Hargous, Nathalie Lapaillerie, Delphine Bonneu, Marc Dechanet-Merville, Julie Legembre, Patrick Capone, Myriam Moreau, Jean-François Taupin, Jean-Luc |
author_sort | Daburon, Sophie |
collection | PubMed |
description | Binding of ligand FasL to its receptor Fas triggers apoptosis via the caspase cascade. FasL itself is homotrimeric, and a productive apoptotic signal requires that FasL be oligomerized beyond the homotrimeric state. We generated a series of FasL chimeras by fusing FasL to domains of the Leukemia Inhibitory Factor receptor gp190 which confer homotypic oligomerization, and analyzed the capacity of these soluble chimeras to trigger cell death. We observed that the most efficient FasL chimera, called pFasL, was also the most polymeric, as it reached the size of a dodecamer. Using a cellular model, we investigated the structure-function relationships of the FasL/Fas interactions for our chimeras, and we demonstrated that the Fas-mediated apoptotic signal did not solely rely on ligand-mediated receptor aggregation, but also required a conformational adaptation of the Fas receptor. When injected into mice, pFasL did not trigger liver injury at a dose which displayed anti-tumor activity in a model of human tumor transplanted to immunodeficient animals, suggesting a potential therapeutic use. Therefore, the optimization of the FasL conformation has to be considered for the development of efficient FasL-derived anti-cancer drugs targeting Fas. |
format | Online Article Text |
id | pubmed-3541234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35412342013-01-16 Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity Daburon, Sophie Devaud, Christel Costet, Pierre Morello, Aurore Garrigue-Antar, Laure Maillasson, Mike Hargous, Nathalie Lapaillerie, Delphine Bonneu, Marc Dechanet-Merville, Julie Legembre, Patrick Capone, Myriam Moreau, Jean-François Taupin, Jean-Luc PLoS One Research Article Binding of ligand FasL to its receptor Fas triggers apoptosis via the caspase cascade. FasL itself is homotrimeric, and a productive apoptotic signal requires that FasL be oligomerized beyond the homotrimeric state. We generated a series of FasL chimeras by fusing FasL to domains of the Leukemia Inhibitory Factor receptor gp190 which confer homotypic oligomerization, and analyzed the capacity of these soluble chimeras to trigger cell death. We observed that the most efficient FasL chimera, called pFasL, was also the most polymeric, as it reached the size of a dodecamer. Using a cellular model, we investigated the structure-function relationships of the FasL/Fas interactions for our chimeras, and we demonstrated that the Fas-mediated apoptotic signal did not solely rely on ligand-mediated receptor aggregation, but also required a conformational adaptation of the Fas receptor. When injected into mice, pFasL did not trigger liver injury at a dose which displayed anti-tumor activity in a model of human tumor transplanted to immunodeficient animals, suggesting a potential therapeutic use. Therefore, the optimization of the FasL conformation has to be considered for the development of efficient FasL-derived anti-cancer drugs targeting Fas. Public Library of Science 2013-01-09 /pmc/articles/PMC3541234/ /pubmed/23326557 http://dx.doi.org/10.1371/journal.pone.0054000 Text en © 2013 Daburon et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Daburon, Sophie Devaud, Christel Costet, Pierre Morello, Aurore Garrigue-Antar, Laure Maillasson, Mike Hargous, Nathalie Lapaillerie, Delphine Bonneu, Marc Dechanet-Merville, Julie Legembre, Patrick Capone, Myriam Moreau, Jean-François Taupin, Jean-Luc Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity |
title | Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity |
title_full | Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity |
title_fullStr | Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity |
title_full_unstemmed | Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity |
title_short | Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity |
title_sort | functional characterization of a chimeric soluble fas ligand polymer with in vivo anti-tumor activity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541234/ https://www.ncbi.nlm.nih.gov/pubmed/23326557 http://dx.doi.org/10.1371/journal.pone.0054000 |
work_keys_str_mv | AT daburonsophie functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT devaudchristel functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT costetpierre functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT morelloaurore functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT garrigueantarlaure functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT maillassonmike functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT hargousnathalie functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT lapailleriedelphine functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT bonneumarc functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT dechanetmervillejulie functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT legembrepatrick functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT caponemyriam functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT moreaujeanfrancois functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity AT taupinjeanluc functionalcharacterizationofachimericsolublefasligandpolymerwithinvivoantitumoractivity |